TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04171401

Intervention type: OTHER
Intervention: In-patient stroke rehabilitation.
Description: An in-patient multi-disciplinary stroke rehabilitation program was performed.
Study: NCT03815409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with partial weight unload
Description: 10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional PT rehabilitation treatment
Description: Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
Study: NCT01991886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm Precision Flow
Description: Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
Study: NCT03649555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FTC-146
Description: Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
Study: NCT03980756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-206 20mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-206 20mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-206 40mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-206 40mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT04660435

Intervention type: DIAGNOSTIC_TEST
Intervention: Thymidine kinase activity
Description: DiviTum® assay determines the enzymatic activity of TK in serum samples
Study: NCT01459315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
Study: NCT03748472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous gavage feeding
Description: Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
Study: NCT00498186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)
Study: NCT03748472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bolus feeding
Description: Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
Study: NCT01267656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricating and Rewetting Drops
Description: Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Blink Contacts Lubricant Eye Drops
Description: Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
Study: NCT00859183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral
Study: NCT04510376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Article
Description: Omeza Collagen Matrix

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: 1.0 mg/mL Histamine Base

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control
Description: Aqueous Negative Control
Study: NCT04485910

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single step media
Description: Usage of single step media in embryo culture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sequential media
Description: Usage of sequential media in embryo culture
Study: NCT02196974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryobiopsy
Study: NCT00674427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD28 Activated T cells
Description: Subjects who are not in CR will receive one infusion of high dose aDLI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD28 Activated T cells
Description: Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
Study: NCT02192073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapectoral Biceps tenodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subpectoral biceps tenodesis
Study: NCT02337738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 1mg
Description: TVP-1012 1mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 0.5mg
Description: TVP-1012 0.5mg Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study: NCT00237185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
Study: NCT03496571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00596297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
Study: NCT04403776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib MR 11 mg
Description: Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
Study: NCT00596297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy
Description: 4 weeks after baseline
Study: NCT04152044

Intervention type: OTHER
Intervention: Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy
Description: Patinets undergoing surgery
Study: NCT04403776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib MR 11 mg
Description: Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib IR 5 mg
Description: Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib IR 5 mg
Description: Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
Study: NCT00376558

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Reinforcement Approach
Description: Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
Study: NCT01228032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care team
Description: The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
Study: NCT00912678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF (Cellcept) and Steroids
Description: Prograf was withdrawn completely after randomization, MMF and steroids were given.
Study: NCT03787147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Google Cardboard
Description: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus
Description: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine Hydrochloride
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
Study: NCT02956148

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [18F]MNI-659
Description: The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
Study: NCT03574363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074 0.25 mg tablet
Description: Oral administration, QD, 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KBP-5074 0.25 mg tablet
Description: Oral administration, QD, 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074 0.5 mg tablet
Description: Oral administration, QD, 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KBP-5074 0.5 mg tablet
Description: Oral administration, QD, 84 days
Study: NCT03576651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1149
Description: Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
Study: NCT00035984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT04467255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative training
Description: 4 weeks aerobic treadmill training compared to endurance training with elastic thera band

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative training
Description: 4 weeks aerobic treadmill training compared to endurance training with elastic thera band
Study: NCT00912678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Prograf)
Description: After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
Study: NCT02159612

Intervention type: OTHER
Intervention: MRI
Description: MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
Study: NCT03405610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Toolkit for Optimal Recovery after Injury
Description: The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
Study: NCT00003099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Daily for 14-28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Daily for 14-28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 14-28 days
Study: NCT02526901

Intervention type: OTHER
Intervention: No intervention
Study: NCT00706810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
Study: NCT00723216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 20 mg twice a day

Intervention type: OTHER
Group type: OTHER
Intervention: Physical prophylaxis
Study: NCT01565642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goals of care decision support
Description: Decision aid and care plan meeting
Study: NCT00263770

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: soft palate implant
Study: NCT00836901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanic acid
Description: 400 mg-57 mg chewable tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin®
Description: 400 mg-57 mg chewable tablet
Study: NCT00263770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft palate implant

Intervention type: OTHER
Group type: OTHER
Intervention: Positive airway pressure (PAP)
Description: which is air delivered by a mask worn over the nose during sleep
Study: NCT03407950

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IPT+
Description: Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
Study: NCT01220583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo radiotherapy
Study: NCT00666354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Study: NCT02196207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eloctate Prophylaxis
Description: Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab Prophylaxis
Description: Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
Study: NCT02034448

Intervention type: PROCEDURE
Intervention: Continuous Renal Replacement Therapy
Study: NCT00613041

Intervention type: PROCEDURE
Intervention: CT Scan
Description: All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
Study: NCT02128009

Intervention type: OTHER
Intervention: osteoporosis